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1. Introduction 
Neurodevelopmental disorders, such as autism spectrum disorder 
(ASD) and schizophrenia (SZ) are likely caused by a combination of 
genetic alterations and environmental insult during early develop-
ment. Although the genetic contribution to these disorders is indis-
putable, increasing evidence points to the role of fetal environment 
(Patterson, 2011; Voineagu et al., 2011; Hagberg et al., 2012; Knuesel 
et al., 2014). For example, twin studies indicate that concordance for 
dizygotic twins is much greater than that for siblings (Hallmayer et 
al., 2011). Further, epidemiological studies show that infections dur-
ing pregnancy increase the risk of ASD and SZ in the offspring (At-
ladottir et al., 2010; Brown, 2012). Evidence of immune dysregulation 
is found in individuals with both disorders; inflammation is present 
in postmortem brains, and cytokine levels are altered in the blood, 
brain, and cerebrospinal fluid in ASD and SZ (Vargas et al., 2005; 
Chez et al., 2007; Patterson, 2009; Morgan et al., 2010; Watanabe et 
al., 2010; Ashwood et al., 2011; Wei et al., 2011). The maternal im-
mune response with altered levels of cytokines in both the mother 
and the offspring is thought to be instigating the brain changes 
and behavioral impairments in these disorders (Girgis et al., 2014). 
Animal studies support the link between maternal immune acti-
vation (MIA) and behavioral abnormalities. Studies on prenatal expo-
sure of rodents and primates to maternal infection or inflammation 
have shown that challenged offspring demonstrate altered behav-
ioral phenotypes relevant to ASD and SZ (Borrell et al., 2002; Fatemi 
et al., 2002; Shi et al., 2003; McAlonan et al., 2010; Ehninger et al., 
2012; Malkova et al., 2012; Bauman et al., 2014). While some stud-
ies failed to detect signs of inflammation in offspring born to im-
mune-challenged mothers (Willi et al., 2013; Missault et al., 2014) 
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Abstract
Both genetic and environmental factors are thought to contribute to neurodevelopmental and neuropsychiatric disorders with maternal immune ac-
tivation (MIA) being a risk factor for both autism spectrum disorders and schizophrenia. Although MIA mouse offspring exhibit behavioral impair-
ments, the synaptic alterations in vivo that mediate these behaviors are not known. Here we employed in vivo multiphoton imaging to determine 
that in the cortex of young MIA offspring there is a reduction in number and turnover rates of dendritic spines, sites of majority of excitatory syn-
aptic inputs. Significantly, spine impairments persisted into adulthood and correlated with increased repetitive behavior, an ASD relevant behavioral 
phenotype. Structural analysis of synaptic inputs revealed a reorganization of presynaptic inputs with a larger proportion of spines being contacted 
by both excitatory and inhibitory presynaptic terminals. These structural impairments were accompanied by altered excitatory and inhibitory syn-
aptic transmission. Finally, we report that a postnatal treatment of MIA offspring with the anti-inflammatory drug ibudilast, prevented both synap-
tic and behavioral impairments. Our results suggest that a possible altered inflammatory state associated with maternal immune activation results in 
impaired synaptic development that persists into adulthood but which can be prevented with early anti-inflammatory treatment. 
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and even showed reduction in inflammatory cytokines in the periph-
ery (Pacheco-Lopez et al., 2013), others have reported increased cy-
tokine levels in the periphery and in the brain (Borrell et al., 2002; 
Garay et al., 2012; Krstic et al., 2012), immune dysregulation (Hsiao 
et al., 2012), as well as neuropathological features such as activated 
microglia (Borrell et al., 2002; Krstic et al., 2012 but see Garay et al. 
2012) and astrocyte activation (Borrell et al., 2002; Fatemi et al., 2002) 
in juvenile or adult animals. 
Alterations in synaptic structure and function are thought to be 
central to many neurodevelopmental disorders including ASD and 
SZ (Marin-Padilla, 1972; Penzes et al., 2011). Neuroanatomical stud-
ies from postmortem brains of individuals with neurodevelopmental 
disorders demonstrate altered number and morphology of dendritic 
spines, which are the postsynaptic structure of excitatory synapses 
(Fiala et al., 2002; Hutsler and Zhang, 2010; Penzes et al., 2011). Sim-
ilarly, synaptic alterations are found in mouse models of these dis-
orders (Comery et al., 1997). Moreover, multiple genetic variations 
associated with neurodevelopmental disorders are found in genes 
that have defined roles in synaptic regulation (Grant, 2012; Peca and 
Feng, 2012). Despite the important role of impaired synaptic devel-
opment in ASD, in vivo analyses of synapse formation and function 
in MIA offspring are limited (Ito et al., 2010; Elmer et al., 2013). More-
over, it is not known whether the synaptic impairments persist into 
adulthood and whether they can be ameliorated with early anti-in-
flammatory treatment. 
Here we report that MIA offspring have reduced dendritic spine 
density and dynamic properties, with impairments persisting into 
adulthood. We also found an alteration in the interaction between 
presynaptic boutons and dendritic spines. These structural impair-
ments were accompanied by deficits in excitatory and inhibitory syn-
aptic transmission. Finally, we found that postnatal treatment with 
an anti-inflammatory drug can prevent the dendritic spine loss as 
well as the increased marble burying in MIA offspring. We suggest 
that an altered inflammatory state in the developing brain of MIA 
offspring affects synaptic development and behavior. 
2. Materials and methods 
2.1. MIA induction 
All protocols were approved by the University of Nebraska Med-
ical Center Institutional Animal Care and Use Committee. YFP-H 
C57Bl/6J pregnant females were bred at UNMC facility with a 12:12 
h light:dark cycle with food and water available ad libitum. Mice 
were mated overnight, and the presence of a vaginal plug on the fol-
lowing morning was noted as embryonic day (E)0.5. Pregnant mice 
were injected intraperitoneally (I.P.) on E12.5 with saline or 20 mg/
Kg Poly (I:C) potassium salt (Sigma Aldrich; St. Louis. MO) (Malkova 
et al., 2012). Pups were allowed to be born naturally. Offspring of sa-
line injected mice are referred to as control offspring and offspring 
of Poly(I:C) injected mice are referred to as MIA offspring. 3–6 litters 
from each condition were used for all experiments. With the excep-
tion of the behavioral data (where 2–5 mice were used per litter), in 
all other experiments no more than 1–3 pups were used from each 
litter. During data collection and analysis the experimenters were 
blind to the experimental conditions. 
2.2. Tissue preparation and immunohistochemistry 
Control and MIA offspring were perfused with 4% paraformalde-
hyde at postnatal day (P)17–19, P30 or at 3–4 months. Brain sections 
(100 microns) containing the somatosensory area were selected for 
analysis. Sections from P30 and 3–4 months old mice were directly 
mounted on slides for imaging. Sections from P17–P19 mice were 
incubated in 10% normal goat serum (NGS) and 0.3% Triton X-100 
for 3 min, washed three times with PBS 1×, pre-incubated 1 h in 5% 
NGS and then immunostained with primary antibodies against GFP 
(polyclonal 1:300, Life Technologies), VGluT1 (polyclonal 1:300, Mil-
lipore), VGluT2 (polyclonal 1:300, Millipore) or GAD-65 (monoclo-
nal 1:100, Developmental Studies Hybridoma Bank) overnight at 4 
°C. The secondary antibodies were Alexa 486, 594 and 647 coupled 
to goat anti-chicken, anti-mouse and anti-guinea pig respectively 
(1:500, 1:200, 1:500 Invitrogen), in 1% NGS and 0.3% Triton X-100, 
for 90 min at RT. 
2.3. Confocal imaging 
Confocal imaging was performed on a Zeiss, LSM 700 using a 40 × 
1.4 N.A oil lens. Images were collected in layer 1 of the S1 region at 
512 × 512 pixels with pixel size of 0.21 μm and Z step of 0.20 μm, 
at 8 bit with 488, 555 and 659 nm lasers. Laser power and gain set-
tings were kept constant for all experiments. 
2.4. Analysis of spine density, morphology and colocalization with 
presynaptic markers 
For quantitative analysis, a 3-D perspective was rendered by the Sur-
pass module of Imaris software package (Version 6.5, Bitplane, Saint 
Paul, MN). Dendritic regions analyzed within the ROI were 30–80 μm 
in length. Spines were classified as stubby, mushroom, thin and filo-
podia based on a hierarchical algorithm (Kim et al., 2013). 
Measurements of VGluT1, VGluT2 and GAD-65 presynaptic 
puncta were made within a ROI of 25 × 25 × 2 μm in layer 1. Puncta 
were individually traced in 3D using the Spot Object package of 
Imaris 6.5 software. All measurements were made within 5–10 mi-
crons from the surface of the section to ensure uniformity of anti-
body penetration. 4–7 ROIs were imaged per mouse. 
Qualitative analysis of colocalization between VGluT1/GAD-65 or 
VGluT2/GAD-65 and dendritic spines was performed on dendrites 
that were within the immunostained volume and on the same fila-
ment previously selected for the density of spines, using the Imar-
isColoc software. After background subtraction, the threshold value 
for each channel was automatically adjusted, following an algorithm 
previously described (Costes et al., 2004). The colocalized voxels rep-
resenting presynaptic puncta on spines were manually counted and 
reported as percent of spines with a colocalized puncta. The den-
dritic parameters (length, width and number of spines counted) for 
the various experiments are included in Supplemental Table 1. 
2.5. Analysis of surface MHCI proteins 
Surface MHCI (sMHCI) staining was performed on fixed brain sec-
tions (100 microns) without permeabilization. Brain section were in-
cubated with monoclonal mouse antibody to MHCI (1:250, OX-18, 
Serotec) together with a VGluT1 antibody (polyclonal 1:300, Milli-
pore) in 5% NGS without Triton X-100 overnight at 4 °C, then washed 
three time in PBS 1×, incubated them with Alexa 486 and 647 (1:500 
and 1:300 respectively) for 90 min and mounted on slides. Measure-
ments of sMHCI were made within a ROI of 10 × 10 × 2 μm in layer 
1. In order to ensure that only surface MHCI was measured rather 
than intracellular protein exposed due to the mechanical damage 
to the surface of the brain section, we used exclusion of VGluT1 
staining (intracellular protein) to determine where in the Z-axis of 
a confocal stack to measure sMHCI (Supplemental Fig. 3). Puncta 
were then individually traced in 3D using the Spot Object package 
of Imaris 6.5 software. 
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2.6. In vivo two-photon imaging 
Thinned-skull cranial windows were prepared above the somatosen-
sory cortex in a single hemisphere of YFP-H C57Bl6/J mice between 
P17 and P19 as previously described (Padmashri et al., 2013). Imag-
ing was performed with a multiphoton microscope (Moving Objec-
tive Microscope (MOM), Sutter), using a Ti:sapphire laser (Chame-
leon Vision II, Coherent) tuned to 925 nm. Images were collected 
with a Nikon water immersion objective (60×, 1.0 NA). For imaging, 
we used ScanImage software (Pologruto et al., 2003) written in MAT-
LAB (MathWorks). During an imaging session, five to six regions of 
interest (ROIs) per animal were selected along the dendritic tufts of 
YFP-expressing layer 5 pyramidal neurons and imaged at intervals 
of 12 min sequentially. Each ROI consisted of a stack of images (20–
40 optical sections, separated axially by 1 μm). Each optical section 
was collected at 512 × 512 pixels, 0.15 μm/pixel. 
2.7. Analysis of spine dynamics 
Dendritic spine analysis was performed using ImageJ software. Den-
dritic segments, 20–60 μm in length, were identified in three-dimen-
sional image stacks taken at different time points, and all spines that 
clearly protruded from the shaft (>0.5 microns) were marked. The 
rates of spines gained and lost were defined, respectively, as the 
fraction of spines that appeared and disappeared between two suc-
cessive frames, relative to the total spine number. Spine turnover rate 
(TOR) was defined as the sum of the spines lost and gained divided 
by twice the total number (Holtmaat et al., 2005). 
2.8. Slice electrophysiology 
Coronal slices containing the S1 area were obtained from P17–
P19 old control and MIA offspring as previously described (Pad-
mashri et al., 2013). For recording, slices were superfused in a 
submersion type recording chamber at room temperature (22–
24 °C) with artificial cerebrospinal fluid (ACSF) saturated with 95% 
O2/5% CO2. Somatic whole-cell recordings were obtained from 
upper layer 2 pyramidal cells of S1 visualized with infrared dif-
ferential interference contrast optics. Recordings were performed 
using an Axoclamp-2B amplifier (Axon Instruments), signals were 
filtered at 3 kHz, digitized (Digidata 1322A; Molecular Devices), 
and sampled at 10 kHz using pClamp 9.0 (Molecular Devices). 
Data was analyzed offline using Mini-Analysis software (Synap-
tosoft). mEPSCs and mIPSCs were recorded at –70 mV. For mEPSC 
recordings, ACSF contained 1 μm TTX (Tocris) and 10 μm bicucul-
line methiodide (Sigma). For mIPSCs recordings, ACSF contained 
1 μm TTX, 20 μm NBQX and 50 μm AP-5. For analysis of mEP-
SCs, 5 min of recording was used. Analysis of mIPSCs was done 
on data recorded for 2 min. 
2.9. Marble burying 
Marble burying is a widely used test of repetitive and perseverative 
behaviors (Thomas et al., 2009). It was performed on 2 months old 
male and female mice. Following acclimatization, 30 glass marbles 
were lightly placed on thick bedding at a 5 × 6 arrangement. Indi-
vidual mice were placed in the cage with the lid closed for 30 min. 
The mouse was then removed and marbles were scored. A marble 
was considered buried if 2/3 of it was covered by bedding. The ob-
server was blinded to the experimental conditions. 
2.10. Drug administration 
Ibudilast (Sigma) was dissolved in corn oil at 5 mg/ml and admin-
istered to lactating dams with an Intraperitoneal (IP) injection daily 
for 2 weeks (starting 24 h post parturition) at a dose of 30 mg/Kg. 
This manner of administration was chosen in order to not stress the 
pups with daily IP injections or gavaging. Control dams received an 
equal dose of vehicle (corn oil) throughout the treatment period. 
Mice were either sacrificed at P17 or weaned at postnatal day 30, 
and were group housed with females and males in separate cages. 
2.11. Statistical analysis 
Data are reported as mean ± s.e.m. For all analysis, with the excep-
tion of Supplemental Figs. 1, 5 and 6, we used n = animals. Normal 
distribution was tested using Kolmogorov–Smirnov test and variance 
was compared. Analysis was done either using two-sided unpaired 
Student’s t-test, multiple t-test with the Sidak–Bonferroni correction, 
one-way ANOVA or two-way ANOVA with the Bonferroni method 
for post hoc multiple comparisons. In two-way ANOVA if interaction 
was not significant a post hoc test was not conducted. Data was an-
alyzed using the Graph Pad Prism software. 
3. Results 
3.1. Reduced dendritic spine density in MIA offspring 
Altered synaptic structure is associated with several neurodevel-
opmental disorders including ASD and has been demonstrated in 
genetic mouse models for these disorders. Previous studies have 
shown that there is a reduction in the number of excitatory syn-
apses in dissociated cortical neurons from MIA offspring (Elmer et 
al., 2013), but whether synaptic impairments are observed in vivo is 
not known. We therefore first investigated if we can detect altered 
density of dendritic spines, postsynaptic sites of excitatory synapses, 
in the cortex of MIA offspring in vivo. Pregnant YFP-H mice were 
injected at E12.5 with 20 mg/Kg Poly (I:C) (MIA) or saline (control). 
In these mice a subset of layer 5 pyramidal neurons are expressing 
YFP (Feng et al., 2000), allowing us to analyze spine density in the 
control and MIA offspring mice (Fig. 1a and b). At P17–19 we found 
a 23% reduction in the density of dendritic spines on layer 1 apical 
dendrites (Fig. 1c, P = 0.018). A similar effect with a 16% reduction 
in spine density was found in the basal dendrites of P30 mice of MIA 
offspring (Suppl. Fig. 1, P = 0.004). These results indicate that in de-
veloping and adolescent mice, maternal immune activation leads to 
reduced density of cortical dendritic spines. 
We next asked if spine morphology was altered in MIA off-
spring. We categorized spines on apical dendrites as mushroom, 
thin, stubby or filopodia. We found that in the MIA offspring at P17–
19 there was a general decrease in all spine categories (Fig. 1d). 
3.2. Impaired dynamics of dendritic spines in vivo 
During development dendritic spines are highly dynamic structures 
with spines appearing and disappearing on a time scale of minutes 
(Dunaevsky et al., 1999). Dendritic spine motility is thought to facil-
itate contacts with axons and mediate the formation of proper neu-
ronal circuitry. Impairments in spine dynamics have been demon-
strated in several mouse models of neurodevelopmental disorders. 
We therefore used transcranial in vivo two-photon laser scanning 
time-lapse microscopy to measure dendritic spine dynamics in intact 
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cortical circuits (Fig. 2a and b). We first confirmed that in this sepa-
rate cohort of mice with spines observed in vivo through a thinned 
skull window the density of spines was reduced in the MIA offspring 
by 22% (Fig. 2c, P = 0.0001). 
We next analyzed the time-lapse images to measure the dynamic 
properties of spines (Fig. 2a and b). We found that dendritic spines 
in MIA offspring were dramatically less dynamic than in control mice 
with a 37% decrease in the turnover rate (TOR) of spines (Fig. 2d, P 
= 0.013). The reduction in TOR was due to both lower rate of spine 
gain (Fig. 2e, P < 0.0001) and reduced rate of spine loss (Fig. 2f, P 
= 0.028). These findings demonstrate that in MIA offspring there 
is impairment in density, morphology and dynamics properties of 
dendritic spines. 
3.3. Altered excitatory and inhibitory presynaptic input in the cortex 
of MIA offspring 
To determine if the altered number, shape and dynamic properties 
of spines are accompanied by alterations in presynaptic inputs, we 
performed a quantitative analysis of excitatory and inhibitory pre-
synaptic puncta using the markers VGluT1, VGluT2 and GAD-65 re-
spectively (Fig. 3a and b and Suppl. Fig. 2). We found no difference 
in the number or size of VGluT1, VGluT2 or GAD-65 puncta in the 
cortex of MIA offspring (Fig. 3c and d). To determine if the synap-
tic inputs reorganized on the remaining dendritic spines in MIA 
offspring we analyzed the colocalization between the YFP labeled 
dendrites and the three synaptic markers (Fig. 3e–f). Although den-
dritic spines are the predominant sites of excitatory synaptic in-
put, recent studies demonstrate that inhibitory inputs on dendritic 
spines are more prevalent than previously appreciated (Chen et al., 
2012). We therefore analyzed the proportion of dendritic spines 
contacted by the excitatory and inhibitory synaptic puncta. We saw 
a trend towards increase in the proportion of spines contacted by 
VGluT1 or GAD-65 puncta in the MIA offspring (Fig. 3h, P = 0.048 
and P = 0.024 respectively) and no change in spines contacted by 
VGluT2 (P = 0.78). These results suggest that while spine density 
is reduced the persisting spines are more likely to be contacted by 
both excitatory and inhibitory presynaptic puncta (Fig. 3h) which 
is consistent with no discernable change in total number of pre-
synaptic puncta (Fig. 3c). Strikingly, in MIA offspring we also found 
a 103% increase in spines that were doubly innervated and con-
tacted by both VGluT1 and GAD-65 puncta (Fig. 3h, P = 0.003). In 
summary these data indicate that in MIA offspring, there is not 
only a decrease in total number of excitatory synapses but also 
a dramatic change in the number of dendritic spines that receive 
multiple synaptic inputs likely resulting in altered processing of in-
coming synaptic inputs. 
3.4. Impaired excitatory and inhibitory synaptic function in MIA 
offspring 
We next examined how MIA affects synaptic function in the cor-
tex. We performed whole-cell voltage-clamp recordings from layer 
2 pyramidal neurons in the somatosensory cortex. While we found 
a 26% decrease (P = 0.007) in the frequency of miniature excitatory 
postsynaptic currents (mESPC), no difference (P = 0.097) was ob-
served in the amplitude of mEPSC in the MIA offspring (Fig. 4a and 
b). These data are consistent with reduced density of dendritic spines 
in the MIA offspring. 
We have also observed altered inhibitory synaptic transmission in 
the MIA offspring (Fig. 4c and d). Although there was no difference 
(P = 0.226) in miniature inhibitory postsynaptic current (mIPSC) fre-
quency, mIPSC amplitude increased by 16% (P = 0.046). Thus MIA 
offspring exhibit both structural and functional impairments in ex-
citatory and inhibitory synaptic transmission. 
3.5. Dendritic spine impairments in MIA offspring can be prevented 
by an anti-inflammatory drug treatment 
Previous studies documented altered expression in the level of cy-
tokines in the brains of the MIA mouse offspring (Garay et al., 2012). 
Cytokines regulate the levels of MHCI, a negative regulator of syn-
apse formation (Glynn et al., 2011) that is increased in neurons from 
MIA offspring (Elmer et al., 2013). We therefore predicted that a re-
duction in an inflammatory state in the MIA offspring during devel-
opment would ameliorate the synaptic deficits. To test this hypoth-
esis we treated control and MIA offspring with an anti-inflammatory 
drug ibudilast during the first 2 postnatal weeks. Ibudilast is a type 
IV-phosphodiesterase inhibitor that modulates the activity of glial 
cells such as the microglia and astrocytes, suppressing the produc-
tion of proinflammatory cytokines (Suzumura et al., 1999; Mizuno 
et al., 2004; Ledeboer et al., 2006). Ibudilast, long used for treatment 
of asthma, can cross the blood brain barrier and in humans can be 
found in breast milk (Web reference: Kyorin Pharmaceuticals; http://
www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/KETAS_Capsules.
pdf). Lactating control and MIA dams were injected with 30 mg/Kg 
ibudilast or vehicle daily for 2 weeks starting 1 day after parturition. 
We have determined that ibudilast can be detected in serum and 
brains of offspring whose lactating mothers received a daily injec-
tion of ibudilast (Supplemental Fig. 4). At P17 the density of den-
dritic spines on apical dendritic tufts in layer 1 of the somatosensory 
cortex was determined. As expected, MIA offspring treated with ve-
hicle had a 17% reduction (P = 0.026) in spine density as compared 
to control mice (Fig. 5a and b). Importantly, treatment of MIA off-
spring with ibudilast resulted in prevention of dendritic spine loss 
(P = 0.007) while having no effect on spine density in control mice 
(P > 0.9). We also tested if an increase in surface MHC class I pro-
teins (sMHCI) can be detected in vivo in MIA offspring and if it can 
be prevented by ibudilast treatment. As has previously been shown 
Fig. 1. Reduced cortical dendritic spine density in young MIA offspring. Con-
focal images of layer 5 pyramidal neuron apical tuft dendrites from P17 off-
spring of control (a) and MIA (b) YFP-H mice. (c) MIA results in a reduction 
in total dendritic spine density (control: 1.014 ± 0.07 spines/micron, n = 4; 
MIA: 0.78 ± 0.04 spines/ micron, n = 6, P = 0.018, unpaired t-test). (d) MIA 
results in a general reduction in density of all dendritic spine categories al-
though these differences did not reach significance following multiple com-
parison corrections (mushroom P = 0.27, stubby P = 0.06, thin P = 0.185 and 
filopodia P = 0.11, multiple t-test with Sidak–Bonferroni correction. Data are 
represented as mean ± SEM.  
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in cultured neurons from MIA offspring (Elmer et al., 2013), we found 
a 37% increase (P = 0.01) in sMHCI staining in cortical sections from 
vehicle treated MIA (Fig. 6a and b). Although there was a 17% reduc-
tion in the expression of sMHCI in ibudilast treated MIA offspring, 
this trend was not significant (P = 0.16). We therefore conclude that 
postnatal anti-inflammatory treatment can prevent spine loss in MIA 
offspring but this is only partially mediated by reduction in sMHCI 
protein expression.  
Fig. 2. Reduced density and dynamics of dendritic spines in MIA offspring. Multiphoton imaging of cortical neurons from P17 YFP-H mice through a thinned 
skull window in control (a) and MIA (b) offspring. Images were collected every 12 min for a period of 1.5 h. Note the reduced density of dendritic protrusions 
in the MIA offspring. Dendritic spine formation (red arrows) and elimination (yellow arrows) is prevalent in control but not MIA offspring. Spines that appear 
but then disappear are marked with an orange arrow. (c–f) Quantification of spine parameters imaged in vivo in 5 mice for each condition (multiple t-tests 
with Bonferroni corrections). Spine density is reduced in MIA offspring (control: 0.92 ± 0.02 spines/micron; MIA: 0.72 ± 0.02 spines/micron, P = 0.0001). Turn-
over rate (TOR) is reduced in MIA offspring (control: 0.091 ± 0.01; MIA 0.057 ± 0.004, P = 0.013) due to reduction in both fraction of spines gained (control: 0.1 
± 0.003; MIA: 0.064 ± 0.004, P < 0.0001) and fraction of spines lost (control: 0.08 ± 0.01; MIA: 0.05 ± 0.005, P = 0.028). Data are represented as mean ± SEM. 
Fig. 3. Altered presynaptic input in the cortex of MIA offspring. (a and b) Cortical P17 sections from YFP-H mice immunostained with VGluT1 (blue) and GAD-
65 (red) in control (a) and MIA offspring (b). (c and d) Quantification of VGluT1, VGluT2 and GAD-65 puncta do not show a reduction in number of puncta in 
MIA offspring. VGluT1, control (black): 307 ± 29.57, n = 8; MIA (red): 285.3 ± 28.15, n = 8, P = 0.60; VGluT2, control: 162.5 ± 32.54, n = 8; MIA: 138.3 ± 18.56, 
n = 6, P = 0.57; GAD-65, control: 174.5 ± 12.7, n = 8; MIA: 154.2 ± 20.56, n = 8, P = 0.41). No significant difference in the volume of the puncta was observed. 
VGluT1, control: 0.305 ± 0.04, n = 6; MIA: 0.264 ± 0.035, n = 8, P = 0.46; VGluT2, control: 0.258 ± 0.048, n = 8; MIA: 0.239 ± 0.012, n = 6, P = 0.75; GAD-65, con-
trol: 0.448 ± 0.073, n = 6; MIA: 0.336 ± 0.027, n = 8, P = 0.13 unpaired t-test). (e and f) Colocalization analysis of VGluT1 and GAD-65 with YFP labeled apical 
tuft dendrites and spines shown in (a) and (b). Arrowheads and arrows denote colocalization of a punctum with a dendritic shaft or spine respectively. Red and 
blue arrows mark colocalization with GAD-65 and VGluT1 puncta respectively. A yellow arrow marks a dendritic spine in a putative contact with both GAD-65 
and VGluT1 puncta. (g) High magnification images of colocalization of presynaptic puncta on dendritic spines showing examples of spines with VGluT1, GAD-
65 and VGluT1 + GAD-65 puncta. (h) Quantification of percent spines contacted by puncta. A non-significant increase in spines contacted by VGluT1, VGluT2 or 
GAD-65 in the MIA offspring (VGluT1, control: 30.24 ± 2.1%, n = 9; MIA: 39 ± 3.5%, n = 9, P = 0.048; VGluT2, control: 25.46 ± 2.84%, n = 6; MIA: 23.92 ± 4.66%, 
n = 6, P = 0.78 and GAD-65, control: 13.02 ± 1.47%, n = 11, MIA: 20.4 ± 2.56%, n = 12, P = 0.024). Quantification of percent of dendritic spines in putative con-
tact with both VGluT1 and a GAD-65 puncta demonstrates an increase in MIA offspring (control: 7.15 ± 1.1%, n = 9; MIA: 14.53 ± 1.78%, n = 9, P = 0.003). Mul-
tiple t-tests with Sidak–Bonferroni corrections were used and only the VGluT1 + GAD category survived the correction. Data are represented as mean ± SEM. 
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3.6. Dendritic spine impairments in MIA offspring persist into 
adulthood 
We next examined if spine loss persists in adult MIA offspring and if 
a 2-week postnatal treatment is sufficient to normalize spine densi-
ties in the adult mice. Lactating dams were treated with 30 mg/Kg 
ibudilast for 2 weeks after birth and at 3 months of age the density 
of dendritic spines on apical dendritic tufts in layer 1 of the somato-
sensory cortex was determined. We found that the dendritic spine 
deficit observed at P17 is maintained into adulthood. There was a 
32% decrease (P = 0.04) in the density of dendritic spines in the 3 
months old vehicle treated MIA offspring as compared to the vehi-
cle treated control offspring (Fig. 7a and b). Although we observed 
a substantial reversal of dendritic spine density impairment in MIA 
offspring whose mothers received a daily injection of ibudilast for 
the first two postnatal weeks (Fig. 7a and b) this result did not reach 
significance (P = 0.26) unless images rather than mice were consid-
ered as N (Suppl. Fig. 5). The control offspring, whose mothers were 
treated with the ibudilast, did not present any changes (P > 0.9) in 
density of spines (Fig. 7a and b). These data indicate that spine def-
icits persist into adulthood in MIA offspring but anti-inflammatory 
treatment during the first two postnatal weeks is not sufficient for 
the spine improvements to persist into adulthood. 
3.7. Anti-inflammatory drug, ibudilast, prevents increased marble 
burying behavior in MIA offspring 
MIA offspring exhibit impairments in several ASD and SZ relevant 
behaviors (Malkova et al., 2012). Marble burying is an assay used to 
test for repetitive and perseverative behaviors (Thomas et al., 2009). 
Previous studies demonstrated that MIA offspring of the same strain 
exhibit increased marble burying (Malkova et al., 2012). We therefore 
tested if treatment with ibudilast can reduce marble burying in MIA 
offspring using the same cohort of mice used for the spine analysis 
above. At postnatal day 60, MIA offspring treated with vehicle bur-
ied 42% more marbles as compared to control mice treated with 
vehicle (Fig. 7c, main effect of prenatal treatment P = 0.0001). We 
found that treatment of MIA offspring with ibudilast during the first 
2 postnatal weeks normalized the marble burying behavior (Fig. 7c, 
main effect of ibudilast treatment, P = 0.0003). Similar results were 
observed when mice from the same litter were averaged (Suppl. Fig. 
6). These findings suggest that prenatal immune activation gener-
ally increased marble burying, whereas ibudilast treatment gener-
ally reduced it. 
We next wanted to determine if there was a relationship be-
tween cortical spine density and marble burying. For a subset of 
mice we had both the marble burying activity at P60 and the sub-
sequent recorded spine density data at 3 months. We found an in-
verse correlation between dendritic spine density and marble bury-
ing (Fig. 7d, r = –0.49, P = 0.048). These data suggest that there is 
a link between cortical spine density and the marble burying defi-
cit in the MIA offspring.  
Fig. 4. Altered cortical excitatory and inhibitory synaptic transmission in the 
MIA offspring. (a) mEPSCs recorded from layer 2 pyramidal neurons in so-
matosensory cortex from control and MIA offspring. (b) Reduced mEPSCs fre-
quency (control (black): 1.22 ± 0.05 Hz, n = 9 mice, 28 cells; MIA (red): 0.90 ± 
0.1 Hz, n = 8 mice, 32 cells, P = 0.007) with no difference in the amplitude of 
mEPSC (control: 15.72 ± 0.44 pA, MIA: 16.91 ± 0.51 pA, P = 0.097) was ob-
served in the MIA offspring. (c) mIPSCs recorded from layer 2 pyramidal neu-
rons in somatosensory cortex from control and MIA offspring. (d) No differ-
ence in mIPSCs frequency (control: 3.82 ± 0.26 Hz, n = 12 mice, 41 cells; MIA: 
3.33 ± 0.29 Hz, n = 9 mice, 35 cells, P = 0.226) and increased mIPSC ampli-
tude (control: 36.51 ± 1.82 pA, MIA: 42.25 ± 1.93 pA, P = 0.046) was observed 
in MIA offspring. Data are represented as mean ± SEM. 
Fig. 5. Postnatal treatment with an anti-inflammatory drug ibudilast, prevents spine loss in young mice. (a) Layer 5 pyramidal neuron apical tuft dendrites from 
P17 control + vehicle, control + ibudilast, MIA + vehicle and MIA + ibudilast offspring mice treated during the first 2 postnatal weeks. (b) Two-way ANOVA 
was first used to test for the presence of interaction between drug treatment and experimental groups. This revealed an interaction consistent with the ob-
servation that ibudilast increased dendritic spine density in the MIA offspring but had no effect on the controls F(1, 20) = 6.296, P = 0.021. Post hoc two-way 
ANOVA with Bonferroni’s correction confirm a reduction in spine density in MIA + vehicle offspring (control + vehicle: 0.89 ± 0.03 spines/micron, n = 6 mice; 
MIA + vehicle: 0.74 ± 0.01 spines/micron, n = 8, mice, P = 0.026) and that reduction is prevented by postnatal treatment with the anti-inflammatory drug ibu-
dilast (MIA + ibudilast: 0.93 ± 0.05 spines/micron, n = 5 mice, MIA + vehicle: 0.74 ± 0.01 spines/micron, n = 8 mice, P = 0.007). No change in spine density 
in control + ibudilast offspring (control + vehicle: 0.89 ± 0.03 spines/micron, n = 6 mice; control + ibudilast: 0.90 ± 0.05 spines/micron, n = 5 mice, P > 0.9).   
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Fig. 7. Dendritic spine impairments in MIA offspring persist into adulthood and are correlated with increased marble burying. (a) Layer 5 pyramidal neuron api-
cal tuft dendrites from 3 month old control + vehicle, control + ibudilast, MIA + vehicle and MIA + ibudilast offspring mice treated during the first 2 postnatal 
weeks. (b) Two-way ANOVA was first used to test for the presence of interaction between drug treatment and experimental groups. This revealed an interaction 
consistent with the observation that ibudilast increased dendritic spine density in the MIA offspring but had no effect on the controls F(1, 19) = 4.62, P = 0.04. 
Post hoc two-way ANOVA with Bonferroni’s correction indicates that a reduction in spine density in MIA + vehicle offspring persists into adulthood (control + 
vehicle: 0.85 ± 0.07 spines/micron, n = 6 mice; MIA + vehicle: 0.58 ± 0.05 spines/micron, n = 6 mice, P = 0.04) but is not prevented by postnatal treatment with 
the anti-inflammatory drug ibudilast (MIA + ibudilast: 0.77 ± 0.09 spines/micron, n = 6 mice, MIA + vehicle: 0.58 ± 0.05 spines/micron, n = 6 mice, P = 0.25). 
No changes in spines density in control + ibudilast offspring (control + vehicle: 0.85 ± 0.07 spines/micron, n = 6 mice; control + ibudilast: 0.77 ± 0.04 spines/
micron, n = 5 mice, P > 0.9). (c) Marble burying is increased in MIA offspring and this increase is prevented by postnatal ibudilast treatment. There was a main 
effect of prenatal treatment, F(1,67) = 16.99, P = 0.0001, as well as a main effect of drug treatment, F(1,67) = 14.37, P = 0.0003 on marble burying but no sig-
nificant interaction F(1,67) = 0.5, P = 0.48. Marble burying increased in MIA offspring (control + veh: 37.7 ± 3.3%, n = 18 mice from 4 litters; MIA + veh: 53.7 ± 
2.7%, n = 18 mice from 4 litters). This increase is reduced in MIA offspring treated with ibudilast during the first 2 postnatal weeks (MIA + Ibud: 37 ± 2.9%, n 
= 17 from 4 litters). There was also a mild effect of ibudilast on control offspring (control + Ibud: 27.6 ± 3.8%, n = 17 from 4 litters). (d) The spine density ob-
served at 3 months is inversely correlated with the percent of marbles buried at P60 (Pearson r = _0.49, n = 18, P = 0.048). Data are represented as mean ± SEM. 
Fig. 6. Surface MHCI proteins are increased in vivo in MIA offspring. (a) Representative confocal images of cortical P17 control + vehicle, control + ibudi-
last, MIA + vehicle and MIA + ibudilast offspring, immunostained for sMHCI. (b) Quantification of surface MHCI. Two-way ANOVA was first used to test for 
the presence of interaction between drug treatment and experimental groups. This revealed an interaction consistent with the observation that ibudilast de-
creased sMHCI in the MIA offspring but had no effect on the controls (F(1, 28) = 6.779, P = 0.015). Post hoc two-way ANOVA with Bonferroni’s correction con-
firms an increase in sMHCI in MIA + vehicle offspring (control + vehicle: 115 ± 12.2 a.u., n = 8; MIA + vehicle: 158.3 ± 9.3 a.u., n = 8, P = 0.01) but the increase 
is not completely prevented by the postnatal treatment with ibudilast (MIA + ibudilast: 130.9 ± 5.7 a.u., n = 8, MIA + vehicle: 158.3 ± 9.3 a.u., n = 8, P = 0.16). 
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4. Discussion 
Here we show that MIA offspring, an environmental risk factor for 
ASD and SZ, exhibit impairments in cortical dendritic spine mor-
phogenesis and motility in vivo with reduced spine density persist-
ing into adulthood. The excitatory and inhibitory connectivity on the 
dendritic spines is altered in the MIA offspring. Functionally, layer 2 
pyramidal neurons receive fewer excitatory synaptic inputs of sim-
ilar strength as well as similar number of inhibitory synaptic inputs 
with increased efficacy in the MIA offspring as in control mice. Fi-
nally, postnatal treatment of MIA offspring with an anti-inflamma-
tory drug ibudilast can ameliorate the spine impairments observed 
in young mice as well as alteration in an ASD relevant behavior, in-
creased marble burying. These data suggest that increased inflam-
matory state during early postnatal weeks is responsible for altered 
synaptic connectivity and impaired behavior and that early anti-in-
flammatory treatment can have an ameliorating effect on both syn-
apses and behavior. 
Although impairments in dendritic spines are a hallmark of many 
neurodevelopmental disorders (Penzes et al., 2011), dendritic spines 
have never been analyzed in MIA offspring. Here we report that MIA 
offspring have a significantly reduced number of dendritic spines 
an impairment that persists into adulthood and therefore could be 
contributing to behavioral deficits observed in adult mice. Reduced 
number and immature appearing dendritic spines have been re-
ported in postmortem SZ brain (Selemon and Goldman-Rakic, 1999; 
Glantz and Lewis, 2000) as well as mouse models for SZ (Lee et 
al., 2011). Although reduced spine density has been reported in a 
MECP2 mutant ASD mouse model (Landi et al., 2011; Jiang et al., 
2013) it is less consistent with most ASD related spine pathophysi-
ology where increase in spine density is more prevalent (Hutsler and 
Zhang, 2010; Penzes et al., 2011). 
During development, dendritic spines are highly dynamic struc-
tures with new spines forming and others disappearing on a time 
scale of minutes (Dailey and Smith, 1996; Dunaevsky et al., 1999). 
While spine motility substantially wanes in adult mice (Dunaevsky et 
al., 1999; Grutzendler et al., 2002; Holtmaat et al., 2005; Cruz-Mar-
tin et al., 2010) it is regulated by sensory experience (Trachtenberg 
et al., 2002) and learning (Xu et al., 2009). Abnormal dendritic spine 
turnover rates have been reported in other mouse models of neu-
rodevelopmental disorders such as Fragile X syndrome (Cruz-Mar-
tin et al., 2010; Pan et al., 2010; Padmashri et al., 2013) and Rett syn-
drome (Landi et al., 2011). Unlike the fmr1 KO (Cruz-Martin et al., 
2010; Pan et al., 2010; Padmashri et al., 2013) and similar to Rett 
mouse model (Landi et al., 2011) in MIA offspring the turnover rate 
of dendritic spine dynamics is substantially reduced, with both for-
mation and elimination of spines being affected. Dendritic spine dy-
namics is thought to facilitate formation of contacts with axons and 
to be necessary for formation of proper circuitry. It is possible that 
the reduced spine dynamics in MIA offspring impairs the ability of 
neurons to modify connectivity in response to experience. 
In addition to the postsynaptic changes we analyzed the presyn-
aptic terminals and their interaction with dendrites and spines. We 
found no overall change in the total number of excitatory presynap-
tic puncta labeled with VGluT1 or VGluT2 in the P17 MIA cortex. To-
gether with the spine density reduction our findings are consistent 
with previous reports of reduced number of excitatory synapses in 
neuronal cultures isolated from MIA brains (Elmer et al., 2013). Based 
on our counts of spines contacted by VGluT1 and VGluT2 puncta we 
estimate that maximally 55% of spines are contacted by an excitatory 
synapse. Although this might seem low one needs to keep in mind 
that at P17 many dendritic spines are transient and these have been 
shown to typically not to be in contact with excitatory presynaptic 
terminals (Knott et al., 2006). We found that MIA results in reorgani-
zation of synapses on dendrites; the proportion of spines contacted 
by VGluT1 but not VGluT2 increases in MIA offspring. While VGluT1 
containing terminals are intracortical in origin, majority of VGluT2 
terminals are of thalamic origin (Hur and Zaborszky, 2005). Differ-
ential regulation of VGluT1 and VGluT2 by activity has been previ-
ously reported (De Gois et al., 2005) and our results suggest circuit 
specific susceptibility to MIA. It is possible that with fewer spines 
available, axons contact previously uninnervated spines as well as 
place a second bouton on an existing synapse. The increase in the 
proportion of VGluT1 innervated spines in MIA offspring is consis-
tent with the observed increased spine stability (Knott et al., 2006). 
We also observed a sizable proportion of spines that are dually in-
nervated by excitatory and inhibitory presynaptic boutons, which 
doubled in MIA offspring. Previous studies have shown that such 
dually innervated spines are particularly prominent on the apical 
dendrites in layer 1 and predominantly involve VGluT2 containing 
terminals in the adult (Kubota et al., 2007). It is possible that during 
development the prevalence of VGluT1 terminals that co-innervate 
a dendritic spine together with an inhibitory synapse is higher than 
in the adults. Although in this study dendritic spines together with 
presynaptic terminals were not imaged dynamically, it is has been 
reported that spines innervated by both excitatory and inhibitory 
synapses are more stable than singly innervated spines (Chen et al., 
2012; Chen and Nedivi, 2013), consistent with reduced turnover rate 
of spines observed in our study. Importantly, our study indicate that 
both pre- and postsynaptic structures are altered in MIA offspring 
and are likely to lead to altered neuronal processing. 
Consistent with structural synaptic alterations, we found altered 
synaptic transmission in the MIA cortex. The reduction in spine den-
sity is consistent with reduced mEPSC frequency. Although the lack 
of change in mIPSC frequency was consistent with a similar number 
of GAD-65 puncta in layer 1, we did not detect an anatomical cor-
relate to the increase in mIPSC amplitude recorded from layer 2 py-
ramidal neurons. Synaptic transmission alterations in MIA offspring 
have also been previously measured in the hippocampus where re-
duced excitatory but not inhibitory synaptic transmission has been 
reported (Ito et al., 2010). The lack of complete electrophysiological 
correlates in our study could be explained by cell and layer specific 
differences as has been previously shown (Dickerson et al., 2014). It 
is also possible that a change in inhibitory synapses that converge 
on cell bodies of neurons (rather than on distal dendrites) more 
directly reflects the electrophysiology recordings. Interestingly, in-
creased GABAA receptors were found on soma and axon initial seg-
ment of pyramidal neurons in the prefrontal cortex of SZ patients 
(Volk et al., 2002). Our findings of reduced excitatory synaptic trans-
mission are consistent with the reduction in synaptic proteins and 
dendritic spines found in SZ brains (Garey et al., 1998; Glantz and 
Lewis, 2000; Harrison and Eastwood, 2001). Alterations in ratio of 
excitation/inhibition are also found in ASD (Zikopoulos and Barbas, 
2013) but the specific disruption depends on the mutation, cell type 
and the synapse studied (Dani et al., 2005; Tropea et al., 2009; Ol-
mos-Serrano et al., 2010; Wallace et al., 2012). 
Altered expression of cytokines and markers of oxidative stress, 
as well as presence of activated astrocytes and microglia, have been 
reported in ASD and SZ brains and suggest that potentially chronic 
neuroinflammatory state can contribute the symptoms and pathol-
ogy of these disorders (Patterson, 2011). The degree to which a pro-
inflammatory profile can be observed systemically and in the brains 
of MIA offspring is still debated, yet alterations in levels of cytokines 
have been observed in fetal (Meyer et al., 2006), postnatal and adult 
brain of MIA offspring (Garay et al., 2012; Krstic et al., 2012) as well 
as altered number of activated microglia and astrocytes (Borrell et al., 
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2002; Krstic et al., 2012). We therefore asked if reducing the inflam-
matory state during early development could ameliorate the syn-
aptic and behavioral impairments. To investigate this possibility, we 
tested the impact of the anti-inflammatory drug ibudilast, a phos-
phodiesterase inhibitor that modulates the activity of glial cells mi-
croglia and astrocytes, suppressing the production of proinflamma-
tory cytokines (Ledeboer et al., 2006). While studies have shown the 
potential of ibudilast in reducing neuroinflammation in a number of 
neurological conditions such as relapsing-remitting multiple scle-
rosis, neuropathic pain and drug abuse (Rolan et al., 2009; Snider et 
al., 2013), there are currently no studies that document evidence in 
ASD. We observed that administration of ibudilast during the first 
2 postnatal weeks through the lactating dam prevented dendritic 
spine impairments in young MIA offspring as well as the increased 
marble burying activity at 2 months. It would be interesting to de-
termine if longer postnatal treatment would result in persistence of 
spine amelioration in older mice. Perseverative and repeated be-
haviors are thought to depend on corticostriatal circuits (Hill, 2004; 
Peca et al., 2011). Although we have not examined synaptic struc-
ture in the most anterior regions of the cortex, pro-inflammatory 
cytokines have been observed in the frontal cortex in MIA offspring 
(Garay et al., 2012). We have also confirmed in vivo that increased 
levels of surface MHCI proteins are expressed in the MIA offspring. 
Since immunological dysfunction in ASD and MIA offspring has been 
found both in the brain and in the peripheral immune system (Hsiao 
et al., 2012; Onore et al., 2014) our experiments cannot distinguish 
the site of action of ibudilast to affect the changes we report here. 
Moreover, effects of the drug on maternal behavior, gut microbiota 
(Hsiao et al., 2013) or epigenetic changes (Basil et al., 2014) have not 
been examined. Although a full pharmacokinetic analysis was be-
yond the scope of this study and therefore the peak levels of ibudi-
last reached in the offspring using lactation as a method of admin-
istration are unknown, we did determine using LC-MS that ibudilast 
was detected in both serum and brains of offspring mice 5 h fol-
lowing injection of lactating dams. Our data suggest therefore that 
reduction in inflammatory cytokines during the period of synapto-
genesis in MIA offspring has long lasting effects indicating a ther-
apeutic potential of ibudilast in treating MIA induced neurodevel-
opmental disorders. 
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Supplemental Material 
Supplementary Method: 
LC-MS/MS measurement of transmission of ibudilast through lactation. Lactating 
mothers were injected with 30mg/Kg ibudilast daily for 2 weeks starting one day after 
parturition. Five hours after the last injection, blood and brain were collected from the 
offspring. The blood was allowed to clot for 30 min after which it was centrifuged at 
15,000 rpm for 15 min and serum was collected and frozen. Brains were homogenized 
in lysis buffer containing protease inhibitors, carried out with 3 cycles of sonication and 
centrifuged at 14,000 rpm for 20 minutes at 4°C. The protein concentration was 
determined using a BCA assay (Pierce, Thermo Scientific). Liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) was used for ibudilast serum 
and brain sample analysis.  A Waters ACQUITY UPLC system (Waters, Milford, MA) 
coupled to an Applied Biosystem 4000 Q TRAP®quadrupole linear ion trap hybrid mass 
spectrometer with an electrospray ionization (ESI) source (Applied Biosystems/MDS 
Sciex, Foster City, CA) was used.  MS/MS analyses were performed in positive 
electrospray ionization mode; specific detection of ibudilast was performed by 
monitoring the transition 231.1→161.1 m/z.  UPLC separation was carried out using an 
ACQUITY UPLC®BEH Shield RP 18 column with a isocratic mobile phase of 0.1% 
formic acid: acetonitrile (1:1, v/v) at a flow rate of 0.25 mL/min. For sample preparation, 
1 mL of ice-cold acetonitrile was added to 50 µL serum or 100 µL brain homogenate 
samples. Samples were then vortexed and centrifuged at 16,000 g for 10 minutes. The 
supernatant was aspirated, evaporated under vacuum, and reconstituted in a 100 µL 
50% acetonitrile.  After centrifugation at 16,000 g for 10 minutes, 10 µL of each sample 
was used for LC-MS/MS analysis. 
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Supplemental Table 1: Dendritic parameters for the various experiments.  
mean±sem	  
 
P17	  Protrusion	  	  (Fig.	  1)	   Con	   MIA	  
Total	  dendrite	  length	  (um)	   1341	   2500	  
Mean	  dendrite	  length	  (um)	   37.4±3.5	   35.8±2.4	  
Mean	  dendrite	  diameter	  (um)	   1.1±0.04	   1.07±0.02	  
Total	  number	  of	  spines	   1338	   1935	  
	  
Colocalization	  (Fig.	  3)	   Con	   MIA	  
Total	  dendrite	  length	  (um)	   690	   805	  
Mean	  dendrite	  length	  (um)	   31.4±2.7	   32.4±1.8	  
Mean	  dendrite	  diameter	  (um)	   1.16±0.03	   1.23±0.05	  
Total	  number	  of	  spines	   661	   574	  
	  
P17	  spines	  (Fig.	  5)	   Con+Veh	   MIA+Veh	   Con+Ibud	   MIA+Ibud	  
Total	  dendrite	  length	  (um)	   836.6	   1078.	   622.7	   792.7	  
Mean	  dendrite	  length	  (um)	   41.6±2.5	   40.17±3.3	   39.3±1.9	   35.4±3.7	  
Mean	  dendrite	  diameter	  (um)	   1.16±0.06	   1.22±0.03	   1.23±0.06	   1.26±0.04	  
Total	  number	  of	  spines	   751	   825	   559	   727	  
	  
Adult	  spines	  (Fig.	  7)	   Con+Veh	   MIA+Veh	   Con+Ibud	   MIA+Ibud	  
Total	  dendrite	  length	  (um)	   1446.4	   1357.4	   700.7	   1153	  
Mean	  dendrite	  length	  (um)	   43.26±1.4	   44.6±1.9	   38.2±3	   45.74±3.1	  
Mean	  dendrite	  diameter	  (um)	   1.08±0.02	   1.07±0.014	   1.2±0.07	   1.17±0.05	  
Total	  number	  of	  spines	   1226	   794	   517	   869	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Supplemental Figure 1: MIA results in a reduction in total dendritic spine density 
on basal dendrites. Example images of basal dendrites from the somatosensory 
cortex in P30 (a) control and (b) MIA offspring. c. Spine densities in Control offspring 
0.68±0.03 spines/µm, n= 48 images, 6 mice and MIA offspring 0.57±0.02, n= 58 images 
from 9 mice P=0.004, unpaired t-test. 
 
 
 
 
 
Supplemental Figure 2: VGluT2 staining in the cortex. Somatosensory sections 
from YFP-H P17 control and MIA offspring immunostained for VGluT2 and GAD-65. 
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Supplemental Figure 3: In vivo analysis of surface expression of MHCI. 
Side view (XZ) of VGluT1 (a) and MHCI (b) staining in unpermeabilized sections 
imaged on a confocal microscope. The top of the section is marked with an arrow. The 
portion of section in which VGluT1 and MHCI colocolized staining is detected (purple in 
c) is not considered for surface analysis. The MHCI staining found in focal planes 
immediately below the colocolized signal (as in the white box) is considered surface 
MHCI staining and is used for analysis.  
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Supplemental Figure 4: Ibudilast can be detected in serum (ng/mL) and brain 
(ng/ng protein) of offspring following transmission of ibudilast through lactation. 
Mean ± SEM, number of pups used are indicated. 
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Supplemental Figure 5: Postnatal treatment with an anti-inflammatory drug 
prevents dendritic spine deficits. Same data as in figure 7b was analyzed with 
N=images.  Two-way ANOVA was first used to test for the presence of interaction 
between drug treatment and experimental groups. This revealed an interaction 
consistent with the observation that ibudilast increased dendritic spine density in the 
MIA offspring but had no effect on the controls F(1, 103)=7.953, P=0.006. Post hoc two-
way ANOVA with Bonferroni’s correction indicates that a reduction in spine density in 
MIA+Vehicle offspring persists into adulthood (control + vehicle: 0.86±0.04 
spines/micron, n=34 images; MIA + vehicle: 0.58±0.03 spines/micron, n=30 images, 
P=0.0006,) but is prevented by postnatal treatment with the anti-inflammatory drug 
Ibudilast (MIA + Ibudilast: 0.78±0.07 ± spines/micron, n=25 images, MIA + vehicle: 
0.58± 0.03 spines/micron, n=30 images, P=0.04). No changes in spines density in 
control+ibudilast offspring (control + vehicle: 0.86±0.04 spines/micron, n=34 images; 
control + ibudilast: 0.75±0.05 spines/micron, n=18 images, P=0.45). 
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Supplemental Figure 6: Marble burying is increased in MIA offspring and is 
reduced by Ibudilast.  Because for the behavioral data 2-5 mice per litter were used 
the data presented in Figure 7c is compiled here while considering litters as 
independent variable. There was a main effect of prenatal treatment, F(1,12)=5.84, 
P=0.03, as well as a main effect of drug treatment, F(1,12)=9.67, P=0.009 on marble 
burying but no significant interaction F(1,12)=1.63, P=0.22. Marble burying increased in 
MIA offspring (con+veh: 38.73±2.76%, n= 4 litters; MIA+veh: 54.48±4.6%, n=4 litters). 
This increase is reduced in MIA offspring treated with ibudilast during the first 2 
postnatal weeks (MIA+Ibud: 35.78±1.46%, n=4 litters). There was a mild effect of 
Ibudilast on control offspring (con+Ibud: 30.96±6.4%, n=4 litters). 	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